Dara-CyBorD vs CyBorD in Newly Diagnosed AL Amyloidosis| Hans Lee, MD | #ASH2024

Dara-CyBorD vs CyBorD in Newly Diagnosed AL Amyloidosis| Hans Lee, MD | #ASH2024

Cevostamab, a FcRH5 bispecific antibody, for RRMM | Joshua Richter, MD | #ASH2024

Cevostamab, a FcRH5 bispecific antibody, for RRMM | Joshua Richter, MD | #ASH2024

Post-CAR-T Driving Restrictions after Week 4 In Myeloma Appear Unnecessary | Rahul Banerjee | #ASH24

Post-CAR-T Driving Restrictions after Week 4 In Myeloma Appear Unnecessary | Rahul Banerjee | #ASH24

24-hour Urine Testing Does Not Add Value to Myeloma Response Assessments | Rahul Banerjee | #ASH24

24-hour Urine Testing Does Not Add Value to Myeloma Response Assessments | Rahul Banerjee | #ASH24

Plasmacytomas are More Genomically Complex than Myeloma in the Bone Marrow | Urvi Shah, MD | #ASH24

Plasmacytomas are More Genomically Complex than Myeloma in the Bone Marrow | Urvi Shah, MD | #ASH24

Daratumumab + Lenalidomide vs Lenalidomide Maintenance in Myeloma | Laahn Foster, MD | #ASH24

Daratumumab + Lenalidomide vs Lenalidomide Maintenance in Myeloma | Laahn Foster, MD | #ASH24

Major side effects of CLL: what patients should prepare for

Can Mass-Fix Replace Bone Marrow Biopsy? | Angela Dispenzieri, MD | #ASH24

Can Mass-Fix Replace Bone Marrow Biopsy? | Angela Dispenzieri, MD | #ASH24

Belantamab Mafodotin with Carfilzomib, Lenalidomide, & Dex for Early Relapse Myeloma | Shebli Atrash, MD | #ASH24

Belantamab Mafodotin with Carfilzomib, Lenalidomide, & Dex for Early Relapse Myeloma | Shebli Atrash, MD | #ASH24

Optimizing Modakafusp Alfa for Relapsed/Refractory Multiple Myeloma | Shebli Atrash, MD | #ASH24

Optimizing Modakafusp Alfa for Relapsed/Refractory Multiple Myeloma | Shebli Atrash, MD | #ASH24

Teclistamab Optec Trial: Prophylactic Toci and Dex during Step-up Doisng | Robert Rifkin, MD | #ASH24

Teclistamab Optec Trial: Prophylactic Toci and Dex during Step-up Doisng | Robert Rifkin, MD | #ASH24

DREAMM-7 Trial Update: Belantamab's Impact on Myeloma Treatment | Robert Rifkin, MD | #ASH24

DREAMM-7 Trial Update: Belantamab's Impact on Myeloma Treatment | Robert Rifkin, MD | #ASH24

MM-6 Trial: In-class transition to Ixazomib in Newly Diagnosed Myeloma | Robert Rifkin, MD | #ASH24